Member Info for moonparty

Not sure where you're looking Balerno, but volume showing 11,900 here:

https://finance.yahoo.com/quote/SCLP.L/

Ditto

It's actually looking promising, offer is increasing with each buy. Probably jinxed it by saying this though.

Personally, I'd like to see minimal price rises before April 6 so I can top up my ISA!

Indeed. It will depend if Calculus have finally cleared their shares. If they have, even thin buy volumes will see price rises.

SEO is simply not relevant for Scancell - nobody is doing deals by searching for "Cancer treatments" on google.

The primary benefit of the website for Scancell is to look professional and provide a starting point for research. So when interested parties follow up and do due diligence they are encouraged.

Minor benefit is to provide investor information, especially PIs, so they don't constantly bother staff with questions.

Thanks vanvan, nice reminder of the incredible results to date.

WTP - none of this is new information, all been announced in RNS, so don't really understand your comment.

Personally, I think Calculus are sold out or very nearly sold out at this stage, and their is a lot of PI's panic selling - hence low volume last couple of weeks and small declines.

Doesn't help all the nonsense posted here and elsewhere, but small caps are generally getting hammered and there is a general shift to risk off.

Logically makes no sense - Scancell are literally on the brink of everything they have worked towards for the last decade, and all results/indications so far is that they have at least 2 blockbuster pipelines. Go figure.

Investor fatigue is also playing a part, a lot of historic kicking the can down the road from Scancell, whether for legitimate scientific reasons are not, has had it's toll on long term investors.

Sorry breaking even, but that is absolute nonsense.

What's new is the detailed results on the patients, that was not in any RNS. It's further confirmation that the scib1 mechanism is the cause of the improved patient results.

As expected, all good.

"Presenting data showing vaccine-specific T cell responses"

So likely to not be headline response figures, but data from patients showing how scib-1 has improved T-cell counts in patients on trial, which is another evidence piece in 'proving' it is substantially better than checkpoint alone. The interested parties will be paying close attention I am sure.

Late yesterday afternoon?

Absolutely rw, common sense, good research and patience will win out in the end.

Just, please, to the sellers, don't put your money in bitcoin 😂

Really don't know why people are saying this is higher risk now than it was 6m, 1y, 2y ago.

The tech is now much closer to commercialisation, and trial results so far are substantially better than standard of care.

I think people are beginning to believe the nonsense that is posted. Oh well, if people are prepared to sell there shares at the current price (probably to the people who are spouting nonsense here and elsewhere) more fool them.

I suppose the positive is that IC reckon Scancell is a hold based on 1 of the 2 genmab deals only 😃

Good to get a mention, but this is incredibly lazy journalism - no mention of the 2 immunotherapy pipeline's currently in human trial. The genmab deal (and there are 2 in play, not 1) really is second fiddle to moditope and immunobody. And no mention of avidimab either.

Looks like it was written by AI with very little checking / validation. Sadly this is one of the negative impacts of AI - too easy to generate competent sounding articles that are misleading and/or inaccurate.

I sincerely hope he doesn't have time to deal with appeasing private investors, that's not what I want from him.

I want him to line up the deals and let LD and the scientists get on with their work.

We have vulpes & redmile to represent shareholders interests - that's good enough for me, don't need constant reassurance.

We will know when they stop selling, anecdotally, because the volume will dry up and the sp will stop falling, and show a sustained rise on a decent RNS. All other things being equal.

Calculus have been under the 3% radar since October, so don't need to report holdings any longer (unless they go back above 3%), so I am not sure how to actually get exact current numbers - possibly have to wait for calculus year-end reports (for all their funds).

This is the link to market screener showing calculus now hold just 2.5 million:

https://uk.marketscreener.com/quote/stock/SCANCELL-HOLDINGS-PLC-6451111/company-shareholders/

Not sure how market screener get their figures or how accurate they are, but it sounds about right, as they were 27 million odd in October, and selling has been intense - appear to have offloaded 25 million since that notification.

That is the main supply tap turned off. And what happens to the supply/demand equation when there is limited supply?

And if Scancell can throw in one of their famed left-field good news RNS's?

I will be going for another top-up once my next monthly DD arrives in my SIPP, and would like to put more in the ISA come April, but suspect it will not be at these bargain prices.